Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by Pareto8020on Jul 30, 2024 11:00am
145 Views
Post# 36154373

RE:Howard and friends failed

RE:Howard and friends failed

It's only been 2+ years since the contract was signed - the ink is barely dry!  

Howard obviously didn't inquire how long it would take them to commercialize the TFC1067 into their product line.  He must have assumed it was going to be a quick turnaround since he convinced the board that going with a minimal upfront payment was the way to go.  Now that could be a double whammy if they don't move forward with the compound - next to no upfront and then possibly zero royalties!  Normally a CEO would be shown the door for such an epic blunder - not at SBM they just continue to pay them salaries for their incompetence and lavish them with free shares and other sweet bonuses.

<< Previous
Bullboard Posts
Next >>